Background: Novel treatment strategies to slow the continued emergence and spread of antimicrobial resistance in Neisseria gonorrhoeae are urgently needed. A molecular assay that predicts in vitro ciprofloxacin susceptibility is now available but has not been systematically studied in human infections.
Methods: Using a genotypic polymerase chain reaction assay to determine the status of the N. gonorrhoeae gyrase subunit A serine 91 codon, we conducted a multisite prospective clinical study of the efficacy of a single oral dose of ciprofloxacin 500 mg in patients with culture-positive gonorrhea. Follow-up specimens for culture were collected to determine microbiological cure 5-10 days post-treatment.
Results: Of the 106 subjects possessing culture-positive infections with wild-type gyrA serine N. gonorrhoeae genotype, the efficacy of single-dose oral ciprofloxacin treatment in the per-protocol population was 100% (95% 1-sided confidence interval, 97.5-100%).
Conclusions: Resistance-guided treatment of N. gonorrhoeae infections with single-dose oral ciprofloxacin was highly efficacious. The widespread introduction and scale-up of gyrA serine 91 genotyping in N. gonorrhoeae infections could have substantial medical and public health benefits in settings where the majority of gonococcal infections are ciprofloxacin susceptible.
Clinical Trials Registration: NCT02961751.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282307 | PMC |
| http://dx.doi.org/10.1093/cid/ciaa596 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implementation of Diagnostics with Macrolide-Resistance Detection Improves Patient Treatment Outcomes in Bulgaria.
Diagnostics (Basel)
November 2024
National Center of Infectious and Parasitic Diseases (NCIPD), 1504 Sofia, Bulgaria.
The increasing prevalence of infections with macrolide-resistance, causing high azithromycin failure rates, is a major concern internationally. In response to this challenge, diagnostics that simultaneously detect and genetic markers for macrolide-resistance enable the therapy to be individually tailored, i.e.
View Article and Find Full Text PDFtreatment outcomes among a cohort failing macrolide resistance-guided treatment across three London sexual health clinics.
Sex Transm Infect
August 2024
Directorate of Sexual Health and HIV Medicine, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Objective: British guidelines advise treatment of () infection using the results of macrolide resistance-associated mutation (MRAM) assays. Limited data informs management when patients fail MRAM-guided treatment. This study evaluates current management strategies employed for cases of infection with MRAM-guided treatment failure.
View Article and Find Full Text PDFCost-effectiveness of resistance-guided therapy for Mycoplasma genitalium in Australia.
Sci Rep
June 2024
School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
The recommended first-line treatment for Mycoplasma genitalium infections is azithromycin. However, the prevalence of macrolide resistance for M. genitalium has increased to more than 50% worldwide.
View Article and Find Full Text PDFMycoplasma genitalium infection and resistance-associated mutations to macrolides and fluoroquinolones among high-risk patients in Taiwan.
J Microbiol Immunol Infect
August 2024
Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:
Background: Mycoplasma genitalium is an emerging etiology of sexually transmitted infections (STIs) with increasing resistance to antimicrobials. Surveillance on the epidemiology of M. genitalium infection and antimicrobial resistance is warranted.
View Article and Find Full Text PDFDetection of Macrolide and/or Fluoroquinolone Resistance Genes in Strains Isolated from Men in the Northwest Region of Croatia in 2018-2023.
Genes (Basel)
April 2024
Clinical Microbiology Department, Teaching Institute of Public Health "Dr Andrija Štampar", 10000 Zagreb, Croatia.
Article Synopsis
- The study investigates the prevalence and resistance trends of non-gonococcal urethritis in male individuals in Croatia, identifying significant rates of macrolide and fluoroquinolone resistance in isolated strains.
- Analyzing 8,073 urine samples collected between 2018 and 2023, researchers found a 2.2% infection rate, with macrolide resistance at 60.4% and fluoroquinolone resistance at 19.2%.
- The study highlights the increasing fluoroquinolone resistance over time and emphasizes the need for better resistance testing and treatment strategies to combat the rising antibiotic resistance in this public health issue.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!